Captiva Verde Land Corp. (CSE: PWR) (OTC: CPIVF) (the “Company”), is pleased to report an update on all of our…
Browsing: BioTech
The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today…
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, congratulates client company Shasqi on the announcement of…
Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively,…
Participating in Ministry of Internal Affairs and Communications project: “Survey Study for International Expansion of AI Diagnosis Support System Using…
Setting the foundation for a new era of endoscopy Olympus Corporation today announced the launch of ENDO-AID(1), a cutting-edge platform…
3-y deal for GI Lite™, low GI white bread for US, Canada & Mexico markets 165 tons for US$1.9m 1st…
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies…
Taiwan’s biotech is gradually emerging. During the COVID-19 epidemic, we had a chance to see the advanced medical equipment and…
Jacobson Pharma Corporation Limited (“Jacobson Pharma” or “the Group”; Stock Code: 2633.HK), a leading company engaged in the research, development,…
Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses focusing on brand protection…
Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further applying its proprietary C1 gene…
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) a global leader in the development of highly effective antiviral therapies based on a…
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development…
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development…
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics…
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”or the “Company”), a biopharmaceutical company focuses on the development of…
AIM ImmunoTech Inc.(NYSE – America交易代碼:AIM)欣然宣布,其已經在猶他州立大學抗病毒研究所確定了一種有效的體外模型,用於測試dsRNA TLR3激動劑Ampligen,該結果表明Ampligen能夠在臨床上可達到的鼻內Ampligen劑量水平下,將SARS-CoV-2感染性病毒的產量降低90%。這一結果支持了AIM制定使用Ampligen預防COVID-19的鼻內預防方法的目標。 AIM首席執行官Thomas K. Equels表示:“我們對這些結果感到滿意,因為它們確立了Ampligen對SARS-CoV-2的生物活性,並支持我們決定在人體內測試Ampligen作為針對COVID-19的鼻內預防和早發療法。” 正常情況下,人源的氣管/支氣管上皮細胞的3D粘膜纖毛組織培養足以模擬一些關鍵的先天免疫反應,現以證明Ampligen對SARS-CoV-2(引起COVID-19的病毒)具有預防作用。在該組織培養模型中觀察到的Ampligen的90%有效濃度(EC90)在臨床上可在人類受試者中實現,以推測可減少SARS-CoV-2。當前,缺少適當的動物模型,因此該公司在正常的人源氣管/支氣管上皮細胞的3-D體外模型中使用了SARS-CoV-2的USA-WA1 / 2020株。結果表明,在臨床上可達到的鼻內Ampligen劑量水平下,Ampligen能夠將SARS-CoV-2感染性病毒產量降低90%。這一結果支持了AIM制定使用Ampligen預防COVID-19的鼻內預防方法的目標。 人們認為Ampligen是人類先天免疫力的強大正調節劑,因此,在動物和人類實驗中,將利用活的體內先天免疫系統獲得最佳的功效度量。 在簡要回顧AIM在SARS樣疾病中的實驗歷史時,Ampligen在先前的SARS-CoV-1病毒動物實驗中顯示出明顯的活性。與SARS-CoV-1病毒小鼠模型相比,Ampligen在鹽水對照組中顯示出100%的保護性生存獲益,而死亡率則為100%。 Ampligen還可以將SARS-CoV-1肺滴度降低至檢測水平以下(Day 2009 https://tinyurl.com/y4sdb8yf 和Barnard 2006 https://tinyurl.com/y68mav9q)。但是,由於尚未設計出具有類似的設計用於復制人類對SARS-CoV-2的人類反應的小鼠的動物模型,因此AIM尋求了體外實驗模型。但是,如前所述,用於病毒實驗的典型細胞系,即克隆的AGM細胞,已經喪失了表達Ampligen生物力學的遺傳能力。這種一般效果是在2006年Barnard等人的表1中首次觀察到的。出版於《抗病毒化學和化學療法》 2006,17:275。 https://tinyurl.com/y68mav9q 另請參閱(https://tinyurl.com/y3k2qs5s) 2006年,Barnard等人在體外模型中認識到這一缺陷。然後使用體內小鼠模型,Ampligen表現出高抗病毒活性,並將SARS-CoV-1的肺滴度降低至檢測水平以下。然後,在2009年的追踪動物實驗中,Ampligen證明了100%的保護性存活,而囓齒類動物的對照組則只有100%的死亡率。 出於這些原因,在等待將來獲得體內動物實驗數據和人類臨床數據的同時,AIM則採用了這種更相關的體外模型,以使用正常,人為或由以下因素組成的模型來證明Ampligen對引起COVID…
Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 “Sihuan Pharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) announced that…
Jacobson Pharma Corporation Limited (“Jacobson Pharma” or “the Group”; Stock Code: 2633.HK), a leading company engaged in the research, development,…